Zarrilli Stephen T reported option exercise involving 25,000 derivative units of GLOBUS MEDICAL INC at $0.00 for $0 on Aug 18, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed Aug 19, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
25,000Stock Option (Right to Buy Class A Common Stock)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Aug 18, 2026Option exercise
Filed
Aug 19, 2026, 5:07 PM ET1-day reporting delay
Accession
0001193125-26-357121Code M · Transaction 11542
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 18, 2026Sell25,000$87.04−$2,175,965Trade 11541
Aug 18, 2026Option exercise25,000$53.27$1,331,750Trade 11540
3 transaction rows in this filing. Joint filers share the same rows.

GMED price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
GMED · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −13%1w ago −3.6%1d ago −3.6%
Returns since7d −5.9%30d −16%90d180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.92 to $87.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. F2: These options were granted on January 22, 2020 and are fully vested.